BBIO News and Press, BridgeBio Pharma Inc.

2026-02-27 02:54:16 ET Shares of antisense therapy concern Ionis Pharmaceuticals, Inc. ( IONS ) have rallied strongly since its familial chylomicronemia syndrome med Tryngolza (olezarsen) bore strong data treating severe hypertriglyceridemia. Announced in September 2025, the res...

2026-02-24 19:28:32 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript BridgeBio Pharma, Inc....

2026-02-24 19:27:51 ET BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call February 24, 2026 4:30 PM EST... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript

2026-02-24 19:08:28 ET Image source: The Motley Fool. Tuesday, Feb. 24, 2026, at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-24 16:06:33 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in...

$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively BridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration...

Interface Inc. (TILE) is expected to report $0.4 for Q4 2025 Evolent Health Inc Class A (EVH) is expected to report $-0.03 for Q4 2025 MercadoLibre Inc. (MELI) is expected to report $11.77 for Q4 2025 Clean Energy Fuels Corp. (CLNE) is expected to report $-0.1 for Q4 2025 Kiniksa ...

2026-02-23 19:20:00 ET The following segment was excerpted from the Allspring Premier Large Company Growth Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Allspring Premier Large Company Growth...

2026-02-23 14:34:32 ET More on CRISPR Therapeutics, Intellia Therapeutics Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Crispr: Emphasis Shifts...

PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will parti...